Shilpa CDMO Commits $50 Million to Peptide Capacity
Shilpa CDMO is investing $50 million to expand commercial peptide manufacturing capacity at an India site, reported by three outlets between 3 and 5 November 2026. All three publications — Indian Pharma Post, Manufacturing Chemist and megaproject.com — agree on the investment figure and the focus on peptide manufacturing. No further details on the specific location, timeline or scope breakdown were available from the headlines.
The investment reflects continued industrial-scale commitment to peptide-based drug manufacturing in India, a segment that has drawn increased attention from contract development and manufacturing organisations in recent years.
| Detail | Information |
|---|---|
| Promoter | Shilpa CDMO |
| Investment Value | $50 million |
| Project Type | Peptide manufacturing capacity expansion |
| Country | India |
| Reported Stage | Announced / Investment committed |
Where India's Pharma Pipeline Stands
Projects India tracks 1,801 live projects in the Drugs and Pharmaceuticals sub-sector, with 18 added in the last 90 days alone. The pipeline is heavily concentrated in a handful of states. Gujarat leads with 608 tracked projects, followed by Telangana at 245, Andhra Pradesh at 231, Karnataka at 216, Maharashtra at 170 and Himachal Pradesh at 59.
This geographic spread reflects the established pharma cluster infrastructure in western and southern India, and signals where suppliers and contractors are most likely to find active procurement activity.
Stage Breakdown: Where the Opportunity Sits
Of the 1,801 tracked projects, the largest cohort — 636 — is at the Under Approvals stage, meaning these projects are progressing through regulatory and statutory clearances and represent near-term tendering opportunities. A further 365 projects have moved into active construction, confirming sustained on-site demand for equipment, materials and services.
Other stages include 323 completed projects, 140 on hold, 137 that have received approvals and are ready to proceed, and 98 at the planning stage. The 137 projects with approvals received but not yet in construction represent a category worth monitoring closely, as these are likely to move to procurement in the near term.
Recent Projects Entering the Tracked Pipeline
Several projects recently added to the Projects India database illustrate the breadth of activity across the sub-sector:
- Granules India Limited — Formulation Manufacturing Plant at Medchal-Malkajgiri, Telangana: Rs 400 crore, Construction Started.
- Sigachi Industries Limited — Pharmaceutical Excipients Plant at Bharuch, Gujarat: Rs 196 crore, Construction Started.
- OneSource Specialty Pharma Limited — Bulk Drugs Project at Bengaluru, Karnataka: Rs 170 crore, Early / Announced.
- Aarti Pharmalabs Limited — API and API Intermediates Plant expansion at Palghar, Maharashtra: Rs 154 crore, Under Approvals.
- Medilux Drugs Private Limited — Bulk Drugs Manufacturing Unit at Pithampur, Dhar, Madhya Pradesh: Rs 31 crore, Approvals Received.
- Besi Drugs Private Limited — APIs and Drug Intermediates Project at Nashik, Maharashtra: Rs 5.26 crore, Construction Started.
These projects span APIs, formulations, excipients and bulk drugs — covering a wide range of manufacturing categories and investment scales, from under Rs 10 crore to Rs 400 crore.
What this means for suppliers and contractors
The Shilpa CDMO announcement adds a dollar-denominated, export-oriented investment to an already active sub-sector. For suppliers and contractors, the immediate read-out from the broader tracked pipeline is more actionable: with 636 projects under approvals and 137 that have already received approvals, the volume of projects approaching active procurement is substantial.
Gujarat remains the single largest state by project count, making it the highest-priority geography for equipment vendors, civil contractors and utility suppliers looking to position ahead of tendering. Telangana, Andhra Pradesh and Karnataka together account for a further 692 tracked projects, reinforcing the importance of the southern cluster.
Peptide manufacturing specifically requires specialised process equipment — reactors, purification systems and lyophilisers — meaning the Shilpa CDMO investment, once further details emerge, is likely to generate procurement opportunities for vendors in those categories. Suppliers active in the CDMO segment should monitor this project as it progresses through approvals and into detailed engineering.
There are currently no open India tenders listed under Industrial Projects on the Projects India platform, but the construction-stage and approvals-received cohorts indicate that tendering activity in pharmaceuticals remains ongoing. Suppliers can track live opportunities at the tenders section.
Frequently asked questions
How much is Shilpa CDMO investing in peptide manufacturing in India?
Shilpa CDMO is investing $50 million to expand commercial peptide manufacturing capacity at an India site. This figure was reported consistently by three outlets — Indian Pharma Post, Manufacturing Chemist and megaproject.com — between 3 and 5 November 2026.
Which Indian states have the most pharmaceutical manufacturing projects?
Based on Projects India tracking data, Gujarat leads with 608 pharmaceutical projects, followed by Telangana at 245, Andhra Pradesh at 231, Karnataka at 216, Maharashtra at 170 and Himachal Pradesh at 59, out of 1,801 live projects in the sub-sector.
How many pharma projects in India are under approvals or ready to start construction?
Projects India tracks 636 Drugs and Pharmaceuticals projects currently under approvals, and a further 137 that have received approvals and are positioned to move into construction, together representing a significant near-term procurement pipeline for suppliers and contractors.


